Results 91 to 100 of about 355,639 (301)

GFAP/BrdU double labeling.

open access: yes, 2013
Immunohistochemical double labeling for GFAP and BrdU shows single GFAP+ astrocytes in the hilus with their processes occasionally extending into the sgz.
Carlos E. N. Girardi (374771)   +6 more
core   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

open access: yesMolecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura   +19 more
wiley   +1 more source

Label-free color staining of quantitative phase images

open access: yesOptics and Lasers in Engineering, 2020
Abstract Phase contrast microscopy enables the label-free visualization of “phase-only” objects such as unstained biological cells. This approach produces a contrast in image intensity that relates qualitatively to the phase delay introduced by the specimen.
Xin Fan   +3 more
openaire   +1 more source

Comparison of SR101-staining in different ages.

open access: yes, 2012
A–C: staining in the ventrolateral medulla (VLM) with 1 µM SR101 for 20 min and 10 min wash out. EGFP-fluorescence is not shown. The SR101 labeling was poor in all three tested ages.
Christian Schnell (117226)   +2 more
core   +1 more source

Flow Enabled Target Capture Halbach‐based magnetic enrichment increases circulating tumor cell capture from blood in metastatic cancer patients

open access: yesMolecular Oncology, EarlyView.
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens   +6 more
wiley   +1 more source

Chondrosarcoma evaluation using hematein-based x-ray staining and high-resolution 3D micro-CT: a feasibility study

open access: yesEuropean Radiology Experimental
Background Chondrosarcomas are rare malignant bone tumors diagnosed by analyzing radiological images and histology of tissue biopsies and evaluating features such as matrix calcification, cortical destruction, trabecular penetration, and tumor cell ...
Alexandra S. Gersing   +11 more
doaj   +1 more source

Enhanced Histochemical Detection of Iron in Paraffin Sections of Mouse Central Nervous System Tissue

open access: yesASN Neuro, 2016
Histochemical methods of detecting iron in the rodent brain result mainly in the labeling of oligodendrocytes, but as all cells utilize iron, this observation suggests that much of the iron in the central nervous system goes undetected.
Scott A. Sands   +4 more
doaj   +1 more source

Cross-labeling MPs from different cell types: non-specific labeling.

open access: yes, 2015
Double staining with annexin-V and specific markers was applied to four MP types (B-lymphocytes, T-lymphocytes, monocytes and NK-cells). Isotypes were used as negative controls (open line) and the tests are presented by filled histogram.
Hugues Duvillier (15585)   +10 more
core   +1 more source

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

open access: yesMolecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder   +10 more
wiley   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

open access: yesMolecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy